Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062573479> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2062573479 endingPage "122" @default.
- W2062573479 startingPage "116" @default.
- W2062573479 abstract "Study Purposes: To determine the maximum-tolerated dose (MTD) of paclitaxel administered by 72-hour continuous infusion followed by bolus intravenous ifosfamide on days 4 and 5 or epirubicin on day 4, every 21 days. To assess the toxicity and preliminary activity in patients with advanced refractory solid tumors. Patients and Methods: Sixteen patients with progressive disease after standard chemotherapy for advanced disease were treated with the combination paclitaxel-ifosfamide and 10 patients with the combination paclitaxel-epirubicin. Results: In the first phase I study the MTDs were: paclitaxel 135 mg/m2 and ifosfamide 2.5 mg/m2/day; hematologic toxicity was the dose-limiting toxicity (DLT) during the first cycle of therapy at dose level 4. Paclitaxel administered at 135 mg/m2 and epirubicin 50 mg/m2 were the MTDs in the second phase I study; grade 4 stomatitis was the DLT of this combination. Conclusions: Paclitaxel by 72-hour continuous infusion followed by bolus ifosfamide was a manageable regimen with an acceptable hematologic toxicity in the absence of neurotoxicity. Preliminary activity of this combination was encouraging in a group of patients with ovarian cancer. The optimal way to combine paclitaxel and epirubicin and the best schedule relative to such a long paclitaxel infusion time in this combination regimen remain to be determined." @default.
- W2062573479 created "2016-06-24" @default.
- W2062573479 creator A5001753228 @default.
- W2062573479 creator A5014932370 @default.
- W2062573479 creator A5026141689 @default.
- W2062573479 creator A5043044349 @default.
- W2062573479 creator A5052795924 @default.
- W2062573479 creator A5065166642 @default.
- W2062573479 date "2001-01-01" @default.
- W2062573479 modified "2023-09-24" @default.
- W2062573479 title "Paclitaxel by 72-Hour Continuous Infusion Followed by Bolus Intravenous Ifosfamide or Epirubicin: Results of Two Phase I Studies" @default.
- W2062573479 cites W1540839883 @default.
- W2062573479 cites W1845622004 @default.
- W2062573479 cites W1879303306 @default.
- W2062573479 cites W1880426265 @default.
- W2062573479 cites W1890813079 @default.
- W2062573479 cites W1950229121 @default.
- W2062573479 cites W1960713055 @default.
- W2062573479 cites W2053026268 @default.
- W2062573479 cites W2066350187 @default.
- W2062573479 cites W2085586686 @default.
- W2062573479 cites W2093749063 @default.
- W2062573479 cites W2100823502 @default.
- W2062573479 cites W2167805334 @default.
- W2062573479 cites W2232368099 @default.
- W2062573479 cites W2240623839 @default.
- W2062573479 cites W99352839 @default.
- W2062573479 doi "https://doi.org/10.1159/000055307" @default.
- W2062573479 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11244325" @default.
- W2062573479 hasPublicationYear "2001" @default.
- W2062573479 type Work @default.
- W2062573479 sameAs 2062573479 @default.
- W2062573479 citedByCount "3" @default.
- W2062573479 crossrefType "journal-article" @default.
- W2062573479 hasAuthorship W2062573479A5001753228 @default.
- W2062573479 hasAuthorship W2062573479A5014932370 @default.
- W2062573479 hasAuthorship W2062573479A5026141689 @default.
- W2062573479 hasAuthorship W2062573479A5043044349 @default.
- W2062573479 hasAuthorship W2062573479A5052795924 @default.
- W2062573479 hasAuthorship W2062573479A5065166642 @default.
- W2062573479 hasConcept C121608353 @default.
- W2062573479 hasConcept C126322002 @default.
- W2062573479 hasConcept C126894567 @default.
- W2062573479 hasConcept C141071460 @default.
- W2062573479 hasConcept C2776694085 @default.
- W2062573479 hasConcept C2776755627 @default.
- W2062573479 hasConcept C2777292972 @default.
- W2062573479 hasConcept C2777506904 @default.
- W2062573479 hasConcept C2777511904 @default.
- W2062573479 hasConcept C2778239845 @default.
- W2062573479 hasConcept C2780835546 @default.
- W2062573479 hasConcept C2781413609 @default.
- W2062573479 hasConcept C29730261 @default.
- W2062573479 hasConcept C42219234 @default.
- W2062573479 hasConcept C43376680 @default.
- W2062573479 hasConcept C530470458 @default.
- W2062573479 hasConcept C71924100 @default.
- W2062573479 hasConcept C98274493 @default.
- W2062573479 hasConceptScore W2062573479C121608353 @default.
- W2062573479 hasConceptScore W2062573479C126322002 @default.
- W2062573479 hasConceptScore W2062573479C126894567 @default.
- W2062573479 hasConceptScore W2062573479C141071460 @default.
- W2062573479 hasConceptScore W2062573479C2776694085 @default.
- W2062573479 hasConceptScore W2062573479C2776755627 @default.
- W2062573479 hasConceptScore W2062573479C2777292972 @default.
- W2062573479 hasConceptScore W2062573479C2777506904 @default.
- W2062573479 hasConceptScore W2062573479C2777511904 @default.
- W2062573479 hasConceptScore W2062573479C2778239845 @default.
- W2062573479 hasConceptScore W2062573479C2780835546 @default.
- W2062573479 hasConceptScore W2062573479C2781413609 @default.
- W2062573479 hasConceptScore W2062573479C29730261 @default.
- W2062573479 hasConceptScore W2062573479C42219234 @default.
- W2062573479 hasConceptScore W2062573479C43376680 @default.
- W2062573479 hasConceptScore W2062573479C530470458 @default.
- W2062573479 hasConceptScore W2062573479C71924100 @default.
- W2062573479 hasConceptScore W2062573479C98274493 @default.
- W2062573479 hasIssue "2" @default.
- W2062573479 hasLocation W20625734791 @default.
- W2062573479 hasLocation W20625734792 @default.
- W2062573479 hasOpenAccess W2062573479 @default.
- W2062573479 hasPrimaryLocation W20625734791 @default.
- W2062573479 hasRelatedWork W1574783687 @default.
- W2062573479 hasRelatedWork W2019200453 @default.
- W2062573479 hasRelatedWork W2028694954 @default.
- W2062573479 hasRelatedWork W2062573479 @default.
- W2062573479 hasRelatedWork W2076102630 @default.
- W2062573479 hasRelatedWork W2239992480 @default.
- W2062573479 hasRelatedWork W2372651819 @default.
- W2062573479 hasRelatedWork W2407247369 @default.
- W2062573479 hasRelatedWork W2418599011 @default.
- W2062573479 hasRelatedWork W288864954 @default.
- W2062573479 hasVolume "60" @default.
- W2062573479 isParatext "false" @default.
- W2062573479 isRetracted "false" @default.
- W2062573479 magId "2062573479" @default.
- W2062573479 workType "article" @default.